Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD319 Antigen (SLAMF7) (SLAMF7)
- Target
- SLAMF7
- Molecular classification
- Immunoglobulin superfamily, SLAM family, Type I transmembrane protein, Receptor
01
Overview
CD319, also known as SLAMF7, is a cell surface glycoprotein belonging to the signaling lymphocyte activation molecule (SLAM) family of receptors. It is expressed on plasma cells (both normal and malignant), natural killer (NK) cells, and cytotoxic T cells. CD319 plays roles in immune regulation, including promoting NK cell cytotoxicity and B cell proliferation. Therapeutically, it is targeted by Elotuzumab for treating multiple myeloma.
- Other names
- CS1CRACC19ACD2 Subset 1FOAP-12
02
Mechanism of action
Antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells
03
Biological functions
Immune responseCell proliferationCell deathSignal transductionNK cell cytotoxicity regulationB cell activation
04
Disease associations
CancerMultiple myelomaImmunodeficiency
05
Safety considerations
Infusion-related reactions with Elotuzumab
06
Interacting drugs
Elotuzumab (Empliciti)
07
Biomarkers
Plasma cell markerMultiple myeloma markerMeasurable residual disease (MRD) monitoring in myeloma
Beyond the preview
Go deeper on CD319 Antigen (SLAMF7) (SLAMF7).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD319 Antigen (SLAMF7) (SLAMF7).